Skip to main
MOLN

MOLN Stock Forecast & Price Target

MOLN Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Molecular Partners is well-positioned in the competitive landscape of proprietary molecular therapeutics, as evidenced by Zai Lab's agreements for DLL3-targeted ADC development with Amgen and Boehringer Ingelheim, and Daiichi Sankyo's licensing of MP0423. Preclinical data for MP0712 and MP0726 support its potential in the rapidly growing field of radioligand therapy, and we expect strong revenue generation (approximately $298M) from MP0712 in treating SCLC and NETs. Additionally, ongoing efforts to improve operational efficiency and profitability, such as AbbVie's licensing of alveltamig, are a positive indicator for the company's long-term success in the market.

Bears say

Molecular Partners is currently collaborating with Orano Med on ten potential programs, and even though they have had some initial success in pre-clinical and clinical development, the company has never been profitable and there is no guarantee that it will ever become profitable. Additionally, the biopharma industry is inherently volatile, and the company may face significant regulatory challenges with their treatments.

MOLN has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Molecular Partners AG and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Molecular Partners AG (MOLN) Forecast

Analysts have given MOLN a Buy based on their latest research and market trends.

According to 2 analysts, MOLN has a Buy consensus rating as of Jul 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Molecular Partners AG (MOLN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.